Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-11-2011 | Retinal Disorders

The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)

Authors: Khaled Nassar, Julia Lüke, Matthias Lüke, Mahmoud Kamal, Effat Abd El-Nabi, Mahmoud Soliman, Martin Rohrbach, Salvatore Grisanti

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 11/2011

Abstract

Background

The cytokine transforming growth factor-ß (TGF-ß) is a pivotal contributor to tissue fibrosis and a key cytokine in the pathogenesis of cellular transdifferentiation, epithelial-mesenchymal transition (EMT), and cell adhesion. This study evaluates the effect of decorin, a naturally occurring TGF-ß inhibitor, in an experimental rabbit model for proliferative vitreoretinopathy (PVR).

Methods

Traumatic PVR was induced in 50 rabbits divided into ten groups (n = 5). One group (GI) reveals a control with no treatment after trauma. Groups (GII–GIV) consisted of subgroups receiving phacovitrectomy at three different time points; (a) at the time of trauma, (b) 1 week following trauma, and (c) 2 weeks following trauma. GIII and GIV received 100 μg or 200 μg decorin, respectively. PVR severity was scored from 0 to 4. The amount of fibrosis was quantified using JMicroVision© software.

Results

The control group GI developed severe PVR with tractional retinal detachment (TRD); (PVR score ≥2) in four rabbits out of five. Vitrectomy had a positive effect (p < 0.05) on PVR development when preformed immediately, however the developed fibrosis was high. The best results were obtained when surgery was used in conjunction with decorin that reduced both the PVR score and fibrosis development significantly (p < 0.05). Depending on dosage and time of vitrectomy, PVR could be completely avoided (PVR score = 0) in 16 rabbits out of 30. TRD was prevented in 13 rabbits out of 15 in GIII to 14 rabbits out of 15 in GIV. In decorin-treated eyes, vitrectomy outcome was best when preformed at 1 week after trauma. There were no drug-related toxic effects evident on clinical and histopathological examination.

Conclusions

In conclusion, in this rabbit model of PVR, adjuvant decorin application during vitrectomy effectively reduces fibrosis and TRD development. In conjunction with no obvious histopathological toxicity signs, decorin represents a promising substance to inhibit PVR reactions.

Available only for authorised users

Tanihara H, Inatani M, Koga T, Yano T, Kimura A (2002) Proteoglycans in the eye. Cornea 21:S62–S69PubMedCrossRef

Hagedorn M, Esser P, Wiedemann P, Heimann K (1993) Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ger J Ophthalmol 2:28–31PubMed

Iozzo R (1999) The biology of the small leucine-rich proteoglycan. J Biol Chem 27:18843–18846CrossRef

Vogel KG, Paulsson M, Heinegard D (1984) Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 223:587–597PubMed

Fleischmajer R, Fisher LW, MacDonald ED, Jacobs L Jr, Perlish JS, Termine JD (1991) Decorin interacts with fibrillar collagen of embryonic and adult human skin. J Struct Biol 106:82–90PubMedCrossRef

Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M (1992) Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 267:5250–5256PubMed

Winnemoller M, Schon P, Vischer P, Kresse H (1992) Interactions between thrombospondin and the small proteoglycan decorin: interference with cell attachment. Eur J Cell Biol 59:47–55PubMed

Lewandowska K, Choi HU, Rosenberg LC, Zardi L, Culp LA (1987) Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain. J Cell Biol 105:1443–1454PubMedCrossRef

Schmidt G, Robenek H, Harrach B, Glössl J, Nolte V, Hörmann H, Richter H, Kresse H (1987) Interaction of small dermatan sulfate proteoglycan from fibroblasts with fibronectin. J Cell Biol 104:1683–1691PubMedCrossRef

10.

Vogel KG, Trotter JA (1987) The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll Relat Res 7:105–114PubMed

11.

Yamaguchi Y, Mann DM, Ruoslahti E (1990) Negative regulation of transforming growth factor- by the proteoglycan decorin. Nature 346:281–284PubMedCrossRef

12.

Takeuchi Y, Kodama Y, Matsumoto T (1994) Bone matrix decorin binds transforming growth factor- and enhances its bioactivity. J Biol Chem 269:32634–32638PubMed

13.

Vial C, Gutierrez J, Santander C, Cabrera D, Brandan E (2011) Decorin interacts with CTGF/CCN2 through LRR12 inhibiting its biological activity. J Biol Chem 2011 Mar 23. [Epub ahead of print]

14.

Nili N, Cheema AN, Giordano FJ, Barolet AW, Babaei S, Hickey R, Eskandarian MR, Smeets M, Butany J, Pasterkamp G, Strauss BH (2003) Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function. Am J Pathol 163:869–878PubMedCrossRef

15.

Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV (1998) Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101:406–412PubMedCrossRef

16.

Iozzo RV, Moscatello DK, McQuillan DJ, Eichstetter I (1999) Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274:4489–4493PubMedCrossRef

17.

Patel S, Santra M, McQuillan DJ, Iozzo RV, Thomas AP (1998) Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca²⁺ in A431 carcinoma cells. J Biol Chem 273:3121–3124PubMedCrossRef

18.

Hausser H, Wedekind P, Sperber T, Peters R, Hasilik A, Kresse H (1996) Isolation and cellular localization of the decorin endocytosis receptor. Eur J Cell Biol 71:325–331PubMed

19.

Rachal WF, Burton TC (1979) Changing concepts of failure after retinal detachment surgery. Arch Ophthalmol 97:480–483PubMed

20.

Kauffmann DJ, van Meurs JC, Mertens DA, Peperkamp E, Master C, Gerritsen ME (1994) Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sic 35:900–906

21.

Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC (1991) Cytokines in proliferative vitreoretinopathy. Eye 5:686–693PubMedCrossRef

22.

Casaroli-Marano RP, Pagan R, Vilaró S (1999) Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 40:2062–2072PubMed

23.

Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784PubMed

24.

Bornstein P (2001) Thrombospondins as matricellular modulators of cell function. J Clin Invest 107:929–934PubMedCrossRef

25.

Shah M, Foreman DM, Ferguson MW (1995) Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sic 108:985–1002

26.

Cordeiro MF, Gay JA, Khaw PT (1999) Human anti-transforming growth factor-2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 40:2225–2234PubMed

27.

Siriwardena D, Khaw PT, King AJ (2002) Human antitransforming growth factor beta (2) monoclonal antibody, a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 190:427–431CrossRef

28.

Grisanti S, Szurman P, Warga M, Kaczmarek R, Ziemssen F, Tatar O, Bartz-Schmidt KU (2005) Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 46:191–196PubMedCrossRef

29.

Cleary PE, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rabbit I. Method of production and natural history. Br J Ophthalmol 63:306–311PubMedCrossRef

30.

Hsu HT, Ryan SJ (1986) Natural history of penetrating ocular injury with retinal laceration in the monkey. Graefes Arch Clin Exp Ophthalmol 224:1–6PubMedCrossRef

31.

Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR (2007) In vivo models of proliferative vitreoretinopathy. Nat Protoc 2:67–77PubMedCrossRef

32.

Vergara O, Ogden T, Ryan SJ (1989) Posterior penetrating injury to the rabbit eye: effect of blood and ferrous ions. Exp Eye Res 49:1115–1126PubMedCrossRef

33.

Cardillo JA, Stout JT, LaBree L, Azen SP, Omphroy L, Cui JZ, Kimura H, Hinton DR, Ryan SJ (1997) Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 104:1166–1173PubMed

34.

Sehu W, Lee W (2005) Ophthalmic pathology: an illustrated guide for clinicians. Blackwell Publishing Ltd, Massachusetts

35.

Cardillo JA, Farah ME, Mitre J, Morales PH, Costa RA, Melo LA, Kuppermann B, Jorge R, Ashton P (2004) An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 88:1201–1205PubMedCrossRef

36.

Roduit N (2010) JMicroVision: Image analysis toolbox for measuring and quantifying components of high-definition images. Version 1.2.2. http://www.jmicrovision.com. Access on 8 January 2010

37.

Charteris DG (1995) Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 79:953–960PubMedCrossRef

38.

Ryan SJ (1985) The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 100:188–193PubMed

39.

Kolb M, Margetts PJ, Sime PJ, Gauldie J (2001) Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 280:L1327–L1334PubMed

40.

Ständer M, Naumann U, Wick W, Weller M (1999) Transforming growth factor-beta and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth. Cell Tissue Res 296:221–227PubMedCrossRef

41.

Merle B, Malaval L, Lawler J, Delmas P, Clezadin P (1997) Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Cell Biochem 67:75–83PubMedCrossRef

42.

Merle B, Durussel L, Delmas PD, Clezardin P (1999) Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 75:538–546PubMedCrossRef

43.

Yamaguchi Y, Ruoslahti E (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336:244–246PubMedCrossRef

44.

De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271:18961–18965PubMedCrossRef

45.

Isaka Y, Brees D, Ikegaya K, Kaneda Y, Imai E, Noble N (1996) Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418–423PubMedCrossRef

46.

Giri S, Hyde D, Braun R, Gaarde W (1997) Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis. Biochem Pharmacol 54:1205–1217PubMedCrossRef

47.

Logan A, Baird A, Berry M (1999) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159:504–510PubMedCrossRef

48.

Fukushima K, Badlani N, Usas A, Riano F, Fu F, Huard J (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29:394–402PubMed

49.

Mohan RR, Gupta R, Mehan MK, Cowden JW, Sinha S (2010) Decorin transfection suppresses profibrogenic genes and myofibroblast formation in human corneal fibroblasts. Exp Eye Re 91:238–245CrossRef

50.

Cleary PE, Larus G, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rhesus monkey: vitreous-lens admixture. Br J Ophthalmol 64:801–808CrossRef

51.

Cleary PE, Ryan SJ (1981) Vitrectomy in penetrating eye injury. Results of a controlled trial of vitrectomy in an experimental posterior penetrating eye injury in the rhesus monkey. Arch Ophthalmol 99:287–292PubMed

52.

Cleary PE, Ryan SJ (1979) Experimental posterior penetrating eye injury in the rabbit II. Histology of wound, vitreous, and retina. Br J Ophthalmol 63:312–321PubMedCrossRef

53.

Hsu HT, Ryan SJ (1986) Experimental retinal detachment in the rabbit. Penetrating ocular injury with retinal laceration. Retina 6:66–69PubMedCrossRef

54.

Margo CE, Lee A (1995) Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefe's Arch Clin Exp Ophthalmol 233:366–370CrossRef

55.

Blumenkranz MS, Ophir A, Clafiin AJ, Kajek A (1982) Fluorouracil for the treatment of massive preretinal proliferation. Am J Ophthalmol 94:458–467PubMed

56.

Fastenberg DM, Diddie KR, Sorgente N, Ryan SJ (1982) A comparison of different cellular innocula in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:559–564PubMed

57.

Fastenberg DM, Diddie KR, Dorey K, Ryan SJ (1982) The role of cellular proliferation in an experimental model of massive periretinal proliferation. Am J Ophthalmol 93:565–572PubMed

58.

Hida T, Chandler DB, Sheta SM (1987) Classification of the stages of proliferative vitreoretinopathy in a refined experimental model in the rabbit eye. Graefes Arch Clin Exp Ophthalmol 225:303–307PubMedCrossRef

59.

Au Eong KG, Kent D, Pieramici DJ (2002) Section III Mechanical globe injuries, chapter 23 vitreous and retina. In: Kuhn F, Pieramici DJ (eds) Ocular trauma principles and practice. Thieme Medical Publishers, New York, p 224

60.

Mittra RA, Mieler WF (1999) Controversies in the management of open-globe injuries involving the posterior segment. Surv Ophthalmol 44:215–225PubMedCrossRef

61.

Spalding SC, Sternberg P Jr (1990) Controversies in the management of posterior segment ocular trauma. Retina 10(Suppl 1):S76–S82PubMed

62.

Wang NK, Chen YP, Yeung L, Chen KJ, Chao AN, Kuo YH, Lee JS, Lai CC (2007) Traumatic pediatric retinal detachment following open globe injury. Ophthalmologica 221:255–263PubMedCrossRef

63.

Ashton P (2006) Retinal Drug Delivery. In: Jaffe JG, Ashton P, Pearson PA (eds) Intraocular drug delivery. Taylor and Francis Group, New York, pp 11–12

64.

Girard P, Mimoun G, Karpouzas I, Montefiore G (1994) Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 14:417–424PubMedCrossRef

65.

Nagasaki H, Shinagawa K (1995) Risk factors for proliferative vitreoretinopathy. Curr Opin Ophthalmol 6:70–75PubMedCrossRef

66.

Mohan RR, Tovey JC, Gupta R, Sharma A, Tandon A (2011) Decorin biology, expression, function and therapy in the cornea. Curr Mol Med 11:110–128PubMed

67.

Meenakshi J, Vidyameenakshi S, Ananthram D, Ramakrishnan KM, Jayaraman V, Babu M (2009) Low decorin expression along with inherent activation of ERK1, 2 in ear lobe keloids. Burns 5:519–526CrossRef

Title: The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)
Authors: Khaled Nassar
Julia Lüke
Matthias Lüke
Mahmoud Kamal
Effat Abd El-Nabi
Mahmoud Soliman
Martin Rohrbach
Salvatore Grisanti
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 11/2011
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-011-1730-9

ACC 2024 Congress

Springer Medicine

The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR)

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2011

Medical retina, focus on retinal imaging, Eds. Frank G. Holz and Richard Spaide, 2010, pp. 227, cloth, EUR 171.15, ISBN-13: 978-3-540-85539-2 Springer-Verlag

Subconjunctival sirolimus in the treatment of diabetic macular edema

Fat repositioning via supraperiosteal dissection with internal fixation for tear trough deformity in an Asian population

Intrastromal corneal ring segment implantation in 219 keratoconic eyes at different stages

Insights into pathology of cuticular drusen from integrated confocal scanning laser ophthalmoscopy imaging and corresponding spectral domain optical coherence tomography

Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration